Announced details
Treatment of chronic cough; add-on therapy to standard treatment for patients with chronic cough whose symptoms have not improved sufficiently with existing treatments
Hyfe's tool has been used in more than 55 clinical trials
The companies are jointly developing KRP-DC125. The app uses a cough monitoring tool owned by Hyfe.
Head office: Wilmington, U.S.; CEO: Tamsin Chislett. Hyfe is a company that provides continuous cough monitoring, objective cough measurement, and cough treatment using digital technology.
Hyfe head office: Wilmington, U.S.
The impact on the forecast for the fiscal year ending March 2027 is minor
The company does not address Contract Value / Offering price.
Japanese Respiratory Society, Cough and Sputum Management Guidelines 2025 [Second Edition]
| Item | Details |
|---|---|
| Names of Products / Services Covered | KRP-DC125, CoughMonitor Suite, ResolveDTx |
| Counterparty | Hyfe Inc. |
| Counterparty overview | Head office: Wilmington, U.S.; CEO: Tamsin Chislett. Hyfe is a company that provides continuous cough monitoring, objective cough measurement, and cough treatment using digital technology. |
| Relationship with the Company | The companies are jointly developing KRP-DC125. The app uses a cough monitoring tool owned by Hyfe. |
| Applicable area | Treatment of chronic cough; add-on therapy to standard treatment for patients with chronic cough whose symptoms have not improved sufficiently with existing treatments |
| Location | Hyfe head office: Wilmington, U.S. |
| Usage history | Hyfe's tool has been used in more than 55 clinical trials |
| Impact on Business Performance | The impact on the forecast for the fiscal year ending March 2027 is minor |
| Source | Japanese Respiratory Society, Cough and Sputum Management Guidelines 2025 [Second Edition] |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide a new treatment option for patients with chronic cough whose symptoms have not improved sufficiently with existing treatments. The trial will evaluate the efficacy and safety of using the app as an add-on to standard treatment.